血液がん診断の市場規模、シェア、動向分析レポート：製品別、検査別、最終用途別、地域別、セグメント予測、2025年～2030年

血液がん診断薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の血液がん診断市場規模は、2025～2030年にかけてCAGR 6.87％を記録し、2030年までに160億4,000万米ドルに達すると予測されています。

市場を牽引するのは、白血病、リンパ腫、骨髄腫などの血液悪性腫瘍の発生率の増加です。さらに、血液がんを含む慢性疾患に罹患しやすい高齢者の増加により、市場は大きく成長すると予想されます。さらに、NGSやその他の分子診断技術を含む技術的進歩により、診断の正確性と効率が向上しており、予測期間にわたって市場を牽引する可能性が高いです。

過去10年間、血液がん診断へのアプローチにおいて大きな進歩が見られ、その目的はすべて、増加する疾病の発生率と死亡率を減少させることにあります。これらの進歩ががんの早期発見を増加させることはよく知られているが、かなりの進歩があった。例えば、NGSはがん細胞の全ゲノムの分析を可能にし、正確な診断とオーダーメイド治療の指針となる遺伝子変異に関する洞察を提供しています。2022年10月、シスメックスのグループ会社であるOGTは、拡大するNGS製品群を強化するため、さまざまな新製品を発表しました。特にSureSeq Myeloid Plusパネルは、様々な骨髄性疾患に関連する遺伝子変異を同定するように設計されており、この重要な研究セグメントにおける同社の能力を強化しています。

SPECT/CT、PET、フローサイトメトリーなどの分子イメージング技術は、分子イメージング薬剤を利用して、さまざまな病期における指標となる分子マーカーを検出し、発見とモニタリングを支援します。このようなイメージング技術の進歩は、精度の向上と早期発見能力を提供し、市場を牽引しています。世界の参入企業は、自動画像検査やシステムを導入して市場シェアを伸ばしています。例えば、2023年5月、シスメックス株式会社は日本でクリニカル・フローサイトメトリーシステムの発売を発表しました。このシステムにはフローサイトメーターXF-1600、サンプル調製システムPS-10、抗体試薬、その他関連製品が含まれます。本システムにより、サンプル調製から測定結果の報告まで、フローサイトメトリー検査の全プロセスを自動化することが可能となり、検査の効率化と標準化に貢献します。

世界中の政府は、白血病やリンパ腫などの血液悪性腫瘍の増加によってもたらされる膨大な医療負担を認識しています。これを受けて、多くの国が早期発見とスクリーニングの努力を優先する包括的な国家がん対策プログラムを立ち上げています。例えば、米国がん研究協会は最近、がん研究を加速させ、米国市民が予防検診をより利用しやすく手頃な価格で受けられるようにするため、Beau Biden Cancer Moonshotイニシアチブを立ち上げました。

同市場の主要企業には、Illumina、InVivoScribe、Ipsogen（Qiagen）、Asuragen（Bio-Techne）、Danaher Corporation、Abbott、SkylineDx、Adaptive Technologies、Bio-Rad Laboratoriesなどがあります。これらの企業は、世界の顧客に対応するため、製品の上市や承認など様々な戦略的取り組みを行っています。例えば、Adaptive Technologiesは2023年9月、血液がんのMRDモニタリング用分子診断検査clonoSEQのEpic統合を開始しました。この統合により、医療従事者はEpicのEHRシステム内でclonoSEQの検査結果を直接注文・確認できるようになり、臨床上の意思決定が効率化され、患者の治療が向上します。

血液がん診断市場レポートハイライト

• 製品別では、アッセイキットと試薬が2024年の血液がん診断薬市場で最大の売上シェアを占めました。この高いシェアは、アッセイキットと試薬が特定のバイオマーカー、遺伝子変異、その他の指標を検出するように設計されており、医療専門家がより効果的に病気を診断・治療できるようになったことに起因します。
• 検査別では、血液検査セグメントが市場を独占し、2024年に最大のシェアを占めました。これは、血液がん検出のための血液検査キットの技術革新と入手可能性が増加していることに起因しています。
• 最終用途別では、病院とクリニックが市場を席巻し、2024年の血液がん診断市場で最大シェアを占めました。これは、法医学ラボや病院の医療ラボにおける疾病診断、血球計数、血液型検査の需要増に起因しています。さらに、病院検査室の開発は、患者の進化するニーズに対応するために極めて重要であり、より多くの病院がその環境で幅広いサービスを提供することを目指しています。
• 北米は白血病のような慢性疾患の罹患率が高く、これらの疾患は定期的なモニタリングや診断検査を必要とするため、先進的診断ツールや技術への需要が高まっている
• アジア太平洋は、2025～2030年までの予測期間において、最も急速な成長が見込まれています。これは、革新的な機器製造能力を持つメーカーが存在し、診断研究能力が加速しているためです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 血液がん診断市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助的な市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 血液がん診断市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 血液がん診断市場：製品別、推定・動向分析

• セグメントダッシュボード
• 血液がん診断市場：製品変動分析
• 2018～2030年の市場規模と予測と動向分析
• 機器
• アッセイキットと試薬

第5章 血液がん診断市場：検査別、推定・動向分析

• 検査市場シェア、2024年と2030年
• セグメントダッシュボード
• 検査による世界の血液がん診断市場展望
• 2018～2030年の市場規模と予測と動向分析
• 血液検査
• 画像検査
• 生検
• 分子検査

第6章 血液がん診断市場：最終用途別、推定・動向分析

• 最終用途市場シェア、2024年と2030年
• セグメントダッシュボード
• 最終用途による世界の血液がん診断市場展望
• 2018～2030年の市場規模と予測と動向分析
• 病院とクリニック
• 診断ラボ
• 研究機関

第7章 血液がん診断市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店とチャネルパートナー一覧
  • 主要企業の市場シェア分析、2024年
  • Illumina
  • InVivoScribe
  • Ipsogen（Qiagen）
  • Asuragen（Bio-Techne）
  • Danaher Corporation
  • Abbott
  • Sequenta（Adaptive bIoTechnologies）
  • SkylineDx
  • Bio-Rad Laboratories
  • Alercell
  • Sophia Genetics

List of Tables

• Table 1 List of abbreviations
• Table 2 North America blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 3 North America blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 4 North America blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 5 North America blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 6 U.S. blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 7 U.S. blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 8 U.S. blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 9 Canada blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 10 Canada blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 11 Canada blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 12 Mexico blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 13 Mexico blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 14 Mexico blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 15 Europe blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 17 Europe blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 18 Europe blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 19 Germany blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 20 Germany blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 21 Germany blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 22 UK blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 23 UK blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 24 UK blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 25 France blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 26 France blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 27 France blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 28 Italy blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 29 Italy blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 30 Italy blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 31 Spain blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 32 Spain blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 33 Spain blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 34 Denmark blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 35 Denmark blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 36 Denmark blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 37 Sweden blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 38 Sweden blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 39 Sweden blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 40 Norway blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 41 Norway blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 42 Norway blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 47 China blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 48 China blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 49 China blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 50 Japan blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 51 Japan blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 52 Japan blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 53 India blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 54 India blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 55 India blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 56 South Korea blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 57 South Korea blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 58 South Korea blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 59 Australia blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 60 Australia blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 61 Australia blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 62 Thailand blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 63 Thailand blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 64 Thailand blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 65 Latin America blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 66 Latin America blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 67 Latin America blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 68 Brazil blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 69 Brazil blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 70 Brazil blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 71 Argentina blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 72 Argentina blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 73 Argentina blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 74 MEA blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 75 MEA blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 76 MEA blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 77 MEA blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 78 South Africa blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 79 South Africa blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 80 South Africa blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 84 UAE blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 85 UAE blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 86 UAE blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 87 Kuwait blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 88 Kuwait blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 89 Kuwait blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Blood cancer diagnostics market: market outlook
• Fig. 14 Blood cancer diagnostics competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Blood cancer diagnostics market driver impact
• Fig. 20 Blood cancer diagnostics market restraint impact
• Fig. 21 Blood cancer diagnostics market strategic initiatives analysis
• Fig. 22 Blood cancer diagnostics market: Product movement analysis
• Fig. 23 Blood cancer diagnostics market: Product outlook and key takeaways
• Fig. 24 Instruments estimates and forecast, 2018 - 2030
• Fig. 25 Assay kits and reagents market estimates and forecast, 2018 - 2030
• Fig. 26 Blood cancer diagnostics Market: Test movement analysis
• Fig. 27 Blood cancer diagnostics market: Test outlook and key takeaways
• Fig. 28 Blood tests market estimates and forecasts, 2018 - 2030
• Fig. 29 Imaging tests market estimates and forecasts,2018 - 2030
• Fig. 30 Biopsy market estimates and forecasts,2018 - 2030
• Fig. 31 Molecular tests market estimates and forecasts,2018 - 2030
• Fig. 32 Blood cancer diagnostics market: End-use movement analysis
• Fig. 33 Blood cancer diagnostics market: End-use outlook and key takeaways
• Fig. 34 Hospitals and clinics market estimates and forecasts, 2018 - 2030
• Fig. 35 Diagnostic labs market estimates and forecasts,2018 - 2030
• Fig. 36 Research institutes market estimates and forecasts, 2018 - 2030
• Fig. 37 Global blood cancer diagnostics market: Regional movement analysis
• Fig. 38 Global blood cancer diagnostics market: Regional outlook and key takeaways
• Fig. 39 Global blood cancer diagnostics market share and leading players
• Fig. 40 North America market share and leading players
• Fig. 41 Europe market share and leading players
• Fig. 42 Asia Pacific market share and leading players
• Fig. 43 Latin America market share and leading players
• Fig. 44 Middle East & Africa market share and leading players
• Fig. 45 North America, by country
• Fig. 46 North America
• Fig. 47 North America market estimates and forecasts, 2018 - 2030
• Fig. 48 U.S. key country dynamics
• Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 50 Canada country dynamics
• Fig. 51 Canada market estimates and forecasts, 2018 - 2030
• Fig. 52 Mexico country dynamics
• Fig. 53 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 54 Europe
• Fig. 55 Europe market estimates and forecasts, 2018 - 2030
• Fig. 56 UK country dynamics
• Fig. 57 UK market estimates and forecasts, 2018 - 2030
• Fig. 58 Germany
• Fig. 59 Germany market estimates and forecasts, 2018 - 2030
• Fig. 60 France country dynamics
• Fig. 61 France market estimates and forecasts, 2018 - 2030
• Fig. 62 Italy country dynamics
• Fig. 63 Italy market estimates and forecasts, 2018 - 2030
• Fig. 64 Spain country dynamics
• Fig. 65 Spain market estimates and forecasts, 2018 - 2030
• Fig. 66 Denmark country dynamics
• Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 68 Sweden country dynamics
• Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 70 Norway country dynamics
• Fig. 71 Norway market estimates and forecasts, 2018 - 2030
• Fig. 72 Asia Pacific
• Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 74 China country dynamics
• Fig. 75 China market estimates and forecasts, 2018 - 2030
• Fig. 76 Japan country dynamics
• Fig. 77 Japan market estimates and forecasts, 2018 - 2030
• Fig. 78 India country dynamics
• Fig. 79 India market estimates and forecasts, 2018 - 2030
• Fig. 80 Thailand country dynamics
• Fig. 81 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 82 South Korea country dynamics
• Fig. 83 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 84 Australia country dynamics
• Fig. 85 Australia market estimates and forecasts, 2018 - 2030
• Fig. 86 Latin America
• Fig. 87 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 88 Brazil country dynamics
• Fig. 89 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 90 Argentina country dynamics
• Fig. 91 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 92 Middle East and Africa
• Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 94 South Africa country dynamics
• Fig. 95 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 96 Saudi Arabia country dynamics
• Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 98 UAE country dynamics
• Fig. 99 UAE market estimates and forecasts, 2018 - 2030
• Fig. 100 Kuwait country dynamics
• Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 102 Market share of key market players- Blood cancer diagnostics market, 2024
• Fig. 103 Company Categorization

Blood Cancer Diagnostics Market Growth & Trends:

The global blood cancer diagnostics market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company's capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care.

Blood Cancer Diagnostics Market Report Highlights:

• Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2024. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively
• Based on tests, blood tests segment dominated the market and accounted for the largest share in 2024. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection
• Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2024. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings
• North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies
• Asia Pacific is expected to witness the fastest growth over the forecast period from 2025 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Test
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Test outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blood Cancer Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of blood cancer
    • 3.2.1.2. Increasing R&D and clinical trials
    • 3.2.1.3. Advancements in diagnostics technologies
    • 3.2.1.4. Rising government initiatives and regulatory support
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High development cost and accessibility barriers
• 3.3. Blood Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Blood Cancer Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Blood Cancer Diagnostics Market: Product Movement Analysis
• 4.3. Blood Cancer Diagnostics Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Assay Kits and Reagents
  • 4.5.1. Assay Kits and Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Blood Cancer Diagnostics Market: Test Estimates & Trend Analysis

• 5.1. Test Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Blood Cancer Diagnostics Market by Test Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Blood Tests
  • 5.5.1. Blood Tests Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Imaging Tests
  • 5.6.1. Imaging Tests Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Biopsy
  • 5.7.1. Biopsy Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Molecular Test
  • 5.8.1. Molecular Tests Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Blood Cancer Diagnostics Market: End-use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Blood Cancer Diagnostics Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospitals and Clinics
  • 6.5.1. Hospitals and Clinics Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Diagnostic Labs
  • 6.6.1. Diagnostic Labs Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Research Institutes
  • 6.7.1. Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Blood Cancer Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/Reimbursement
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/Reimbursement
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/Reimbursement
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/Reimbursement
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/Reimbursement
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/Reimbursement
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/Reimbursement
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/Reimbursement
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/Reimbursement
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/Reimbursement
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/Reimbursement
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/Reimbursement
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/Reimbursement
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/Reimbursement
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/Reimbursement
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/Reimbursement
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/Reimbursement
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/Reimbursement
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/Reimbursement
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/Reimbursement
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/Reimbursement
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/Reimbursement
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Illumina
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Services benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. InVivoScribe
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Services benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Ipsogen (Qiagen)
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Services benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Asuragen(Bio-Techne)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Services benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Danaher Corporation
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Services benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Abbott
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Services benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Sequenta (Adaptive biotechnologies)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Services benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. SkylineDx
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Services benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Bio-Rad Laboratories
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Services benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Alercell
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Services benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Sophia Genetics
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Services benchmarking
    • 8.3.14.4. Strategic initiatives